RxDoctor Payments Data

Erin Butler, PA

Physician Assistant · Lexington, KYNPI 1194141127

Payments from drug & device makers

$5,583in general payments, 2019–2025

Across 242 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$591
  • Novartis$341
  • Regeneron Healthcare Solutions, Inc.$339
  • Merck$335
  • Pfizer$285
  • AbbVie$283
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$5,48298%
  • Education$1012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,583 in reported general payments places this provider in the 90th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$15,710
Medicare patients
165
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate11$188,870
JadenuDeferasirox16$156,660
ZarxioFilgrastim-Sndz11$37,676
Abiraterone Acetate20$32,425
Imatinib Mesylate16$27,064
XareltoRivaroxaban21$24,244
EliquisApixaban27$15,865
Exemestane18$1,885
Anastrozole97$1,837
Anagrelide Hcl13$1,354
Hydroxyurea44$1,130
Letrozole41$1,038
Tamoxifen Citrate15$632
Ondansetron Hcl13$604
Dexamethasone16$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Jadenu$341$345,53027 claims
Johnson & JohnsonXarelto$214$24,24421 claims
PfizerEliquis$285$15,86527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →